Work-up of head and neck cancer with synchronous lung nodules: diagnostic and therapeutic challenge

Eliçin, Olgun (March 2022). Work-up of head and neck cancer with synchronous lung nodules: diagnostic and therapeutic challenge. Radiotherapy and oncology, 168(S 2), pp. 35-36. Elsevier

Purpose or Objective
Head and neck squamous cell carcinoma (HNSCC) often presents with synchronous nodules of the lung (SNL), as either benign nodules, pulmonary malignancies or metastases of HNSCC. Our aim was to convey an understanding about what is suggested as the proposed and best work-up for such cases, to provide an overview on publications until the year 2020 and to fill the literature gap regarding synchronous primary malignancies of the lung (SPML) and HNSCC.

Materials and Methods
In line with the PRISMA guidelines, two authors conducted a systematic search in the PubMed database independently. Searches combined disease and incidence specific terms, using the Boolean operator functions in all searches. All articles were evaluated according to the Oxford Centre of Evidence Based Medicine (OCEBM) levels.

Results
From a total of 2591 abstracts, 70 abstracts were narrowed down to 48 full-text articles. 27 papers, published until 2020, could be included for data extraction. Most of the publications were on OCEBM level 2a and 2b. Mean and median sample sizes were 674 and 399 cases, respectively. SNL ranged from 2-49%, whereas SPML ranged from 0.4-6.9% (median: 2.7%) of
all patients. Most patients report smoking history (53-100%). Chest X-ray, CT and PET/CT yield mean sensitivity of 55%, 93%, 96%, mean specificity of 97%, 97%, 96%, positive predictive value of 67%, 78%, 80% and negative predictive value of 78%, 98% and 96%, respectively. The mean and median survival times after curative treatment of SPML were 22 and 19
months (range: 12-45), respectively.

Conclusion
2.7% of patients with HNSCC have SPML. Based on these results, the use of 18FDG-PET/CT at the time of diagnosis and swift
aggressive concomitant or sequential curative treatment of the SPML to the HNSCC is recommended.

Item Type:

Conference or Workshop Item (Abstract)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Eliçin, Olgun

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0167-8140

Publisher:

Elsevier

Language:

English

Submitter:

Basak Ginsbourger

Date Deposited:

05 May 2023 14:10

Last Modified:

05 May 2023 14:10

URI:

https://boris.unibe.ch/id/eprint/182301

Actions (login required)

Edit item Edit item
Provide Feedback